Optic IconOptic Logo
|
SearchCollectionsBenchmarks
Clinical trial

Early and Late Prognosis in Patients With Guillain-Barre Syndrome

ID
Name
Dengbinbin
Description
The goal of this observational study is to explore significant indicators to predict the early prognosis and late prognosis in patients with Guillain-Barre syndrome.
Trial arms
Trial start
2013-01-02
Estimated PCD
2022-12-01
Trial end
2025-01-31
Status
Recruiting
Phase
Early phase I
Treatment
Intravenous Immunoglobulins, Human
patients were treated with intravenous immunoglobulin(30g ivgtt qd) for 5 days
Arms:
immunoglobulin group, mixed group
Methylprednisolone 500 MG Injection
patients were treated with methylprednisolone
Arms:
methylprednisolone group, mixed group
Size
450
Primary endpoint
the severity of Guillain-barre syndrome
baseline, at 1 week, at 26 weeks
Eligibility criteria
Inclusion Criteria: * patients fulfilled clinical, biological, and electrophysiology criteria for Guillain-barre syndrome. Exclusion Criteria: * nonidiopathic Guillain-barre syndrome and Miller Fisher syndrome
Protocol
{'studyType': 'INTERVENTIONAL', 'phases': ['PHASE4'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'primaryPurpose': 'PREVENTION', 'maskingInfo': {'masking': 'DOUBLE', 'whoMasked': ['PARTICIPANT', 'CARE_PROVIDER']}}, 'enrollmentInfo': {'count': 450, 'type': 'ESTIMATED'}}
Updated at
2023-09-18

1 organization

1 product

1 drug

1 indication

Organization
First Affiliated Hospital of Wenzhou Medical University
Drug
IVIG
Indication
Guillain-Barre Syndrome
Product
Methylprednisolone